Genentech and Roche have filed for yet another indication for Avastin. The filing is for Avastin combined with chemotherapy in relapsed metastatic colorectal cancer. It is based on a late-stage trial that saw a 25 percent reduction in the risk of death and a 33 percent improvement in overall survival compared to patients receiving a standard chemotherapy regime alone. In the first three quarters of this year Avastin has racked up $911 million in sales.
- read this report from Pharmaceutical Business Review for more